Skip to content

Adalimumab is an important option within the psoriasis treatment armamentarium

Adalimumab is an important option within the psoriasis treatment armamentarium 1

The approval of adalimumab is an important milestone in particular for children with severe disease because it extends the armamentarium of the physicians who are working to reduce the burden of this chronic disease in this sensitive young patient population, said Marieke M. The prevalence of the disease in childhood and adolescence ranges between 0. It must be clarified to them that psoriasis does not have a permanent cure, and therefore the main goal of treatments is to establish disease control and prolonged periods between flares. Keywords: adolescent psoriasis, pediatric psoriasis, treatment, systemic treatment, biologic agents. 12 Although it is considered a relatively safe treatment option with almost no systemic absorption, its use is limited, due to the staining of the skin and the local irritation it provokes. Ustekinumab is the most recent biological therapy to join the armamentarium against psoriasis gaining registration in both the United States and the European Union in 2009 (see Table 1 ). The TNF class of biologics (etanercept, infliximab, and adalimumab) appeared following the initial registration of both alefacept and efalizumab (see Table 1 ). Psoriasis is a lifelong disorder with a major impact on patients’ QOL.

Evidence has accumulated in the past that psoriasis is a chronic inflammatory systemic disease. Since several years the armamentarium of psoriasis treatment has been broadened by the availability of TNF alpha blockers. The effects of adalimumab will be compared with those of fumaric acids, which represent an established traditional systemic treatment option for moderate to severe psoriasis. This article reviews the current biologic therapies for the treatment of psoriasis and psoriatic arthritis, discusses the importance of patient and clinician education in the decision-making process and highlights drugs in the pipeline. The proven efficacy and safety of biologics has added to the armamentarium of treatment options for patients suffering from psoriasis and PsA. Joint disease is associated with psoriasis in a significant proportion of patients (reported in one study to be 13. Management options for the treatment of psoriasis include: 1. Third-line therapy which refers to systemic biological therapies that use molecules designed to block specific molecular steps important in the development of psoriasis, such as the TNF antagonists adalimumab, etanercept and infliximab, and ustekinumab, anti-IL12-23 monoclonal antibody.

Genetics also are an important component of psoriasis, with 30 percent of psoriasis patients having a relative with the condition. Seven biosimilar agents are under development for adalimumab, whose patent expires at the start of 2017. There are a variety of plaque psoriasis medications and treatments available. What is the most important information I should know about HUMIRA? Psoriasis is a prevalent condition in the United States, estimated to affect 7.4 million adults on the basis of 2013 estimates. 12 Health care practitioners should also ensure that patients provide comprehensive medical histories before treatment options are discussed, which is particularly important in the setting of systemic therapy, whether it be with older agents such as methotrexate or cyclosporine or with biologics. The armamentarium of medications used to treat patients with moderate to severe psoriasis has grown continually in recent years. Currently, commonly used and approved systemic agents in the United States include methotrexate (with folate supplementation), cyclosporine, oral retinoids (acitretin), and apremilast, and 4 biologic agents, namely, etanercept, infliximab, adalimumab, and ustekinumab.

The Influence Of Adalimumab On Cardiovascular And Metabolic Risk In Psoriasis

Currently available therapeutic options for rheumatoid arthritis (RA) entail disease-modifying anti-rheumatic drugs (DMARDs; e. Newer drugs in the treatment armamentarium that have shown efficacy for both psoriasis and psoriatic arthritis consist of the anti-IL-17 agent, secukinumab, and a phosphodiesterase-4 inhibitor, apremilast. JAK inhibitors have been studied in early phase trials for psoriasis patients, and the data are promising for these agents as potential treatment options. Additionally, tofacitinib s inhibition of IL-15 may play an important role in treating psoriasis as IL-15 is highly expressed with enhanced binding activity in psoriatic lesions and associated with increased resistance to keratinocyte apoptosis 28. Physician says variety of treatment choices allows for individualized patient care. Adalimumab also appears to positively benefit psoriatic arthritis. This makes phototherapy and narrowband UVB important options in psoriasis treatment, he says. There are places for all of the treatments that have been developed for psoriasis, and it is good that we have this increasing armamentarium of therapies so that you can use the best treatment available for appropriate patients, Dr. Etanercept therapy was discontinued, and adalimumab therapy, 40 mg weekly for the first 4 weeks, was initiated. The patient subsequently experienced decreased efficacy of the drug in the treatment of psoriasis and psoriatic arthritis and discontinued the therapy.

Expanded Knowledge Opens Doors To Improved Psoriasis Treatments